Novartis 3Q Revenues: $14.3 billion (+4%) 3Q Earnings: $2.3 billion (-6%) YTD Revenues: $42.8 billion (+2%) YTD Earnings: $7.2 billion (-2%) Comments: Pharmaceutical sales were $7.9 billion in the quarter, up 1%, offset by generic competition for Diovan (-14% to $835 million). Oncology sales were $2.7 billion, up 2%, driven by Afinitor (+65% to $337 million), Tasigna (+25% to $315 million), Exjade (+9% to $212 million) and Sandostatin (+7% to $401 million), offset by Zometa (-66% to $104 mi...